Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia

Hasan Mahmud, Steven M. Kornblau, Arja ter Elst, Frank J. G. Scherpen, Yi Hua Qiu, Kevin R. Coombes, Eveline S. J. M. de Bont*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

20 Citaten (Scopus)
309 Downloads (Pure)


The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in similar to 15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression.

Originele taal-2English
Aantal pagina's3
TijdschriftJournal of Hematology & Oncology
Nummer van het tijdschrift1
StatusPublished - 3-aug.-2016


Duik in de onderzoeksthema's van 'Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit